280 related articles for article (PubMed ID: 23223128)
1. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
2. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Sevko A; Michels T; Vrohlings M; Umansky L; Beckhove P; Kato M; Shurin GV; Shurin MR; Umansky V
J Immunol; 2013 Mar; 190(5):2464-71. PubMed ID: 23359505
[TBL] [Abstract][Full Text] [Related]
4. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
5. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.
Fujimura T; Ring S; Umansky V; Mahnke K; Enk AH
J Invest Dermatol; 2012 Apr; 132(4):1239-46. PubMed ID: 22189788
[TBL] [Abstract][Full Text] [Related]
7. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
9. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V; Sevko A
Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
[TBL] [Abstract][Full Text] [Related]
10. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments.
Blidner AG; Salatino M; Mascanfroni ID; Diament MJ; Bal de Kier Joffé E; Jasnis MA; Klein SM; Rabinovich GA
J Immunol; 2015 Apr; 194(7):3452-62. PubMed ID: 25740944
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
12. Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells.
Umansky V; Sevko A
Pigment Cell Melanoma Res; 2013 Jul; 26(4):457-63. PubMed ID: 23560814
[TBL] [Abstract][Full Text] [Related]
13. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
[TBL] [Abstract][Full Text] [Related]
14. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
15. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B
J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.
Shime H; Kojima A; Maruyama A; Saito Y; Oshiumi H; Matsumoto M; Seya T
J Innate Immun; 2014; 6(3):293-305. PubMed ID: 24192491
[TBL] [Abstract][Full Text] [Related]
18. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
19. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Neoplasia; 2013 Dec; 15(12):1400-9. PubMed ID: 24403862
[TBL] [Abstract][Full Text] [Related]
20. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.
Jayaraman P; Parikh F; Lopez-Rivera E; Hailemichael Y; Clark A; Ma G; Cannan D; Ramacher M; Kato M; Overwijk WW; Chen SH; Umansky VY; Sikora AG
J Immunol; 2012 Jun; 188(11):5365-76. PubMed ID: 22529296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
